Search results for " Middle"

showing 10 items of 1097 documents

New stratigraphical data on the Middle-Late Jurassic biosiliceous sediments from the Sicanian basin, Western Sicily (Italy)

2008

The reported data present the stratigraphy of several sections across a Middle–Late Jurassic Radiolaritic Unit, well exposed in different thrust sheets pertaining to the Maghrebian chain of Southwestern Sicily. The aim was to define the chronostratigraphical distribution of the Jurassic biosiliceous sedi- mentation in the Sicanian palaeogeographical zone, a deep water basin belonging to the Southern Tethys continental margin. The radiolarian biostratigraphy indicates that the switching from carbonate to siliceous sedimentation in the Sicanian Basin is referable to the Bajocian, as shown by the section of Campofiorito, near Corleone. The biostratigraphical dataset allows the correlation betw…

BasaltMiddle-Late JurassicbasaltsGeologychertsBiostratigraphyStructural basinDeep waterradiolariansPaleontologyMiddle–Late JurassicContinental marginStratigraphyradiolarians; biostratigraphy; cherts; basalts; Middle–Late Jurassic; SicilybiostratigraphySiliceous sediments Mesozoic Sicily Jurassic radiolariaSicilyGeology
researchProduct

10-Year Clinical Experience With 18F-Choline PET/CT: An Italian Multicenter Retrospective Assessment of 3343 Patients.

2020

Purpose The primary aim of this multicenter retrospective analysis is to examine the role of(18)F-choline PET/CT as a diagnostic tool for staging and restaging prostate cancer (PCa) in a large population in the light of 10 years of clinical experience. A secondary aim of the study is to produce data on the predictors of a positive(18)F-choline PET/CT result in the setting of PCa primaries and biochemical recurrences. Materials and Methods This multicenter retrospective cohort study is based on data collected by 9 Italian nuclear medicine departments. Between October 2008 and September 2019, 3343 men underwent(18)F-choline PET/CT scans before receiving definitive treatments for a primary PCa…

Biochemical recurrenceMalemedicine.medical_specialtyProstate biopsyrecurrencePET/CTcholine; PET/CT; prostate cancer; recurrence; staging030218 nuclear medicine & medical imagingCholine03 medical and health sciencesProstate cancer0302 clinical medicineSettore MED/36ProstatePositron Emission Tomography Computed Tomography80 and overMedicineHumansRadiology Nuclear Medicine and imagingTomographyCancer stagingAgedAged 80 and overPET-CTmedicine.diagnostic_testbusiness.industryProstatic NeoplasmsRetrospective cohort studyGeneral MedicinestagingMiddle Agedmedicine.diseaseprostate cancerX-Ray ComputedProstate-specific antigenmedicine.anatomical_structurePET030220 oncology & carcinogenesisRadiologyNeoplasm GradingRadiopharmaceuticalsbusinessSettore MED/36 - Diagnostica Per Immagini E RadioterapiaTomography X-Ray ComputedCT; choline; prostate cancer; recurrence; staging; Aged; Aged 80 and over; Choline; Humans; Male; Middle Aged; Neoplasm Grading; Positron Emission Tomography Computed Tomography; Prostatic Neoplasms; Radiopharmaceuticals; Tomography X-Ray ComputedCTClinical nuclear medicine
researchProduct

Hysteroscopic Evaluation of Endometrial Changes in Breast Cancer Women with or without Hormone Therapies: Results from a Large Multicenter Cohort Stu…

2020

ABSTRACT Study Objective The primary aim of our study was to investigate the incidence of endometrial pathologies, especially endometrial cancer, in women with breast cancer treated with tamoxifen (TAM), aromatase inhibitors (AIs), or receiving no treatment (NT). The secondary aim was to identify, in this cohort, ultrasonographic findings that represent robust indications for hysteroscopy and endometrial biopsy, to avoid unnecessary second-level diagnostic procedures. Design Multicenter retrospective cohort study (Clinical Trial ID: NCT03898947). Setting Data were collected from different Italian centers: Regina Elena National Cancer Institute of Rome, Arbor Vitae Centre of Rome, Gaetano Ma…

BiopsyAromatase inhibitors Breast cancer Endometrial cancer Endometrial pathologies Tamoxifen Adult Aged Aged 80 and over Antineoplastic Agents Hormonal Biopsy Breast Neoplasms Cohort Studies Endometrial Hyperplasia Endometrial Neoplasms Endometrium Female Humans Hysteroscopy Incidence Middle Aged Polyps Precancerous Conditions Pregnancy Retrospective Studies Tamoxifen Uterine Diseases Uterine NeoplasmsCohort StudiesEndometrium0302 clinical medicineBreast cancerEndometrial cancerPregnancyAromatase inhibitors; Breast cancer; Endometrial cancer; Endometrial pathologies; TamoxifenAged 80 and overUterine Diseases030219 obstetrics & reproductive medicinemedicine.diagnostic_testEndometrial pathologiesIncidenceObstetrics and GynecologyMiddle AgedAromatase inhibitorsHysteroscopy030220 oncology & carcinogenesisEndometrial HyperplasiaUterine NeoplasmsFemalemedicine.drugAromatase inhibitors Breast cancer Endometrial cancer Endometrial pathologies TamoxifenAdultmedicine.medical_specialtyAntineoplastic Agents HormonalBreast NeoplasmsHysteroscopy03 medical and health sciencesBreast cancerPolypsmedicineEndometrial PolypHumansAgedRetrospective StudiesGynecologybusiness.industryEndometrial cancerCancerRetrospective cohort studymedicine.diseaseEndometrial NeoplasmsTamoxifenbusinessPrecancerous ConditionsTamoxifenEndometrial biopsy
researchProduct

Quality of life following urinary diversion: Orthotopic ileal neobladder versus ileal conduit. A multicentre study among long-term, female bladder ca…

2019

Abstract Introduction Women undergoing radical cystectomy (RC) followed by urinary diversion (UD) for bladder cancer experience a substantial reduction in health-related quality of life (HRQOL). At present, studies comparing long-term QOL outcomes for different UD methods, needed to inform evidence-based choices of bladder reconstruction for female patients, are sparse. Our objective was to compare two common UD methods in terms of their HRQOL outcomes in women. Materials and methods We retrospectively analysed HRQOL in 73 consecutive female bladder cancer patients having undergone orthotopic ileal neobladder (IONB, N = 24) or ileal conduit (IC, N = 49) following RC between 2007 and 2013 in…

Bladder cancer; Ileal conduit; Orthotopic neobladder; Quality of life; Radical cystectomy; Women;Time Factorsmedicine.medical_treatment030232 urology & nephrologyUrinary DiversionBladder cancer; Ileal conduit; Orthotopic neobladder; Quality of life; Radical cystectomy; Women; Adult; Aged; Aged 80 and over; Cancer Survivors; Cross-Sectional Studies; Female; Follow-Up Studies; Humans; Ileum; Italy; Middle Aged; Surveys and Questionnaires; Survival Rate; Time Factors; Urinary Bladder Neoplasms; Urinary Diversion; Quality of Life; Urinary Reservoirs Continent; Surgery; Oncology0302 clinical medicineCancer SurvivorsQuality of lifeSurveys and QuestionnairesOrthotopic neobladder80 and overSurveys and QuestionnaireStage (cooking)Aged 80 and overSettore MED/24 - UROLOGIABladder cancerUrinary Reservoirs ContinentGeneral MedicineMiddle AgedhumanitiesSurvival RateIleal conduitItalyOncology030220 oncology & carcinogenesisUrinary Bladder NeoplasmFemaleCancer SurvivorUrinary ReservoirsHumanQuality of lifeAdultmedicine.medical_specialtyTime FactorFollow-Up StudieCystectomy03 medical and health sciencesIleumInternal medicinemedicineHumansWomenPathologicalAgedCross-Sectional StudieBladder cancerbusiness.industryUrinary diversionCancermedicine.diseaseRadiation therapyRadical cystectomyContinentCross-Sectional StudiesBladder cancer; Ileal conduit; Orthotopic neobladder; Quality of life; Radical cystectomy; WomenUrinary Bladder NeoplasmsSurgerybusinessFollow-Up StudiesEuropean Journal of Surgical Oncology
researchProduct

A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.

2015

BACKGROUND: Obesity is a chronic disease with serious health consequences, but weight loss is difficult to maintain through lifestyle intervention alone. Liraglutide, a glucagon-like peptide-1 analogue, has been shown to have potential benefit for weight management at a once-daily dose of 3.0 mg, injected subcutaneously. METHODS: We conducted a 56-week, double-blind trial involving 3731 patients who did not have type 2 diabetes and who had a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of at least 30 or a BMI of at least 27 if they had treated or untreated dyslipidemia or hypertension. We randomly assigned patients in a 2:1 ratio to receive on…

Blood GlucoseCounselingMaleType 2 diabeteslaw.inventionBody Mass IndexRandomized controlled trialWeight losslawGlucagon-Like Peptide 1Weight managementSubcutaneousMedicine (all)ReducingNauseaGeneral MedicineMiddle AgedCombined Modality Therapy3. Good healthFemaletype 2 diabetesmedicine.symptomHumanmedicine.drugAdultDiarrheamedicine.medical_specialtyDiet ReducingInjections SubcutaneousInjections SubcutaneouPlaceboInjectionsDouble-Blind MethodInternal medicineWeight LossmedicineHumansHypoglycemic AgentsObesityExerciseHypoglycemic AgentLiraglutidebusiness.industryLiraglutidemedicine.diseaseWeight LoDietEndocrinologybusiness[SDV.AEN]Life Sciences [q-bio]/Food and NutritionBody mass index[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyDyslipidemiaAdult; Blood Glucose; Body Mass Index; Combined Modality Therapy; Counseling; Diarrhea; Diet Reducing; Double-Blind Method; Exercise; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Injections Subcutaneous; Liraglutide; Male; Middle Aged; Nausea; Obesity; Weight Loss; Medicine (all)The New England journal of medicine
researchProduct

Influence of dietary fat and carbohydrates proportions on plasma lipids, glucose control and low-grade inflammation in patients with type 2 diabetes—…

2015

Purpose: The optimal macronutrient composition of the diet for the management of type 2 diabetes is debated, particularly with regard to the ideal proportion of fat and carbohydrates. The aim of the study was to explore the association of different proportions of fat and carbohydrates of the diet—within the ranges recommended by different guidelines—with metabolic risk factors. Methods: We studied 1785 people with type 2 diabetes, aged 50–75, enrolled in the TOSCA.IT Study. Dietary habits were assessed using a validated food-frequency questionnaire (EPIC). Anthropometry, fasting lipids, HbA1c and C-reactive protein (CRP) were measured. Results: Increasing fat intake from <25 to ≥35 % is …

Blood GlucoseDietary FiberMale0301 basic medicineGlycated Hemoglobin AGlucose controlMedicine (miscellaneous)Type 2 diabetesSettore MED/13 - Endocrinologia0302 clinical medicineRisk FactorsSurveys and QuestionnairesDietary fatfat plsam lipids low-grade inflammationNutritional guidelinesNutrition and DieteticsbiologyType 2 diabetesMiddle AgedHDL-cholesterolCholesterolC-Reactive ProteinCarbohydrates diet fat Glucose control HDL-cholesterol Nutritional guidelines Triglycerides Type 2 diabetesCarbohydrates; Diet; Fat; Glucose control; HDL-cholesterol; Nutritional guidelines; Triglycerides; Type 2 diabetesFemaleDietary ProteinsType 2Dietary Carbohydratesmedicine.medical_specialtyHDLCarbohydrates030209 endocrinology & metabolismLDL03 medical and health sciencesInternal medicineGlucose controlPlasma lipidsDiabetes MellitusDietary CarbohydratesmedicineHumansIn patientCarbohydrates; Diet; Fat; Glucose control; HDL-cholesterol; Nutritional guidelines; Triglycerides; Type 2 diabetes; Medicine (miscellaneous); Nutrition and DieteticsTriglyceridesAgedGlycated HemoglobinInflammation030109 nutrition & dieteticsbusiness.industryCholesterol HDLC-reactive proteinCholesterol LDLAnthropometrymedicine.diseaseDietary FatsDietEndocrinologyDiabetes Mellitus Type 2Fatbiology.proteinDiet · Carbohydrates · Fat · Glucose control · HDL-cholesterol · Triglycerides · Type 2 diabetes · Nutritional guidelinesCarbohydrates; Diet; Fat; Glucose control; HDL-cholesterol; Nutritional guidelines; Triglycerides; Type 2 diabetes; Aged; Blood Glucose; C-Reactive Protein; Cholesterol HDL; Cholesterol LDL; Diabetes Mellitus Type 2; Dietary Carbohydrates; Dietary Fats; Dietary Fiber; Dietary Proteins; Energy Intake; Female; Glycated Hemoglobin A; Humans; Inflammation; Male; Middle Aged; Risk Factors; Surveys and Questionnaires; TriglyceridesEnergy IntakebusinessEuropean Journal of Nutrition
researchProduct

Severe hypoglycemia is associated with antidiabetic oral treatment compared with insulin analogs in nursing home patients with type 2 diabetes and de…

2015

Abstract Objectives Severe hypoglycemia is associated with cognitive decline and dementia in older persons with type 2 diabetes. The role of antidiabetic treatments on severe hypoglycemia is unknown in dementia. The aims were to determine the prevalence of severe hypoglycemic events and investigate associations among severe hypoglycemic and specific antidiabetic treatments (classes of oral agents and types of insulin analogs) in a large sample of nursing home patients with diabetes according to dementia status. Design Cross-sectional observational study. Setting A total of 150 nursing homes across Italy. Participants A total of 2258 patients with type 2 diabetes (dementia = 1138, no dementi…

Blood GlucoseMaleAgingSevere hypoglycemia dementia insulin analogs antidiabetic oral agents agingmedicine.medical_treatmentInsulin analogAdministration OralType 2 diabetesSeverity of Illness IndexInsulin AntagonistsReference ValuesOdds RatioPrevalenceHomes for the AgedInsulinReference ValueCognitive declineNursing (all)2901 Nursing (miscellaneous)General NursingAged 80 and overInsulin AntagonistMedicine (all)Health PolicyAging; Antidiabetic oral agents; Dementia; Insulin analogs; Severe hypoglycemia; Administration Oral; Age Distribution; Aged; Aged 80 and over; Blood Glucose; Confidence Intervals; Cross-Sectional Studies; Dementia; Diabetes Mellitus Type 2; Female; Homes for the Aged; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Antagonists; Italy; Logistic Models; Male; Middle Aged; Nursing Homes; Odds Ratio; Prevalence; Prognosis; Reference Values; Risk Assessment; Severity of Illness Index; Sex Distribution; Sulfonylurea Compounds; Nursing (all)2901 Nursing (miscellaneous); Health PolicyGeneral MedicineMiddle AgedPrognosisSulfonylurea CompoundNursing HomeItalyFemaleHumanmedicine.medical_specialtyLogistic ModelPrognosiHypoglycemiaelderly patientsRisk AssessmentAge DistributionInternal medicineDiabetes mellitusmedicineConfidence IntervalsDementiaHumansHypoglycemic AgentsSex DistributionAgedAntidiabetic oral agentCross-Sectional StudieSevere hypoglycemiaHypoglycemic Agentbusiness.industryInsulinOdds ratiomedicine.diseaseHypoglycemiaNursing HomesEndocrinologyCross-Sectional StudiesLogistic ModelsSulfonylurea CompoundsDiabetes Mellitus Type 2DementiaGeriatrics and GerontologybusinessConfidence IntervalBody mass indexJournal of the American Medical Directors Association
researchProduct

3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-…

2017

Background: \ud Liraglutide 3·0 mg was shown to reduce bodyweight and improve glucose metabolism after the 56-week period of this trial, one of four trials in the SCALE programme. In the 3-year assessment of the SCALE Obesity and Prediabetes trial we aimed to evaluate the proportion of individuals with prediabetes who were diagnosed with type 2 diabetes.\ud \ud Methods: \ud In this randomised, double-blind, placebo-controlled trial, adults with prediabetes and a body-mass index of at least 30 kg/m2, or at least 27 kg/m2 with comorbidities, were randomised 2:1, using a telephone or web-based system, to once-daily subcutaneous liraglutide 3·0 mg or matched placebo, as an adjunct to a reduced-…

Blood GlucoseMaleEXENATIDEType 2 diabetes030204 cardiovascular system & hematologyBody Mass Indexlaw.inventionPlacebosImpaired glucose toleranceMELLITUS3.0 MG0302 clinical medicineRandomized controlled trialGlucagon-Like Peptide 1lawPREVENTION PROGRAM OUTCOMESPrediabetesPREVENTION PROGRAM OUTCOMES; IMPAIRED GLUCOSE-TOLERANCE; LIFE-STYLE; CLINICAL-TRIAL; OBESE SUBJECTS; 3.0 MG; REGRESSION; EXENATIDE; MELLITUSSubcutaneousMedicine (all)General MedicineMiddle AgedAdult; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus Type 2; Double-Blind Method; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incretins; Injections Subcutaneous; Liraglutide; Male; Middle Aged; Obesity; Placebos; Prediabetic State; Risk Reduction Behavior; Treatment Outcome; Weight Loss3. Good healthTreatment OutcomeFemaleLIFE-STYLEType 2OBESE SUBJECTSmedicine.drugAdultmedicine.medical_specialtyInjections Subcutaneous030209 endocrinology & metabolismPlaceboIncretinsGlucagon-Like Peptide-1 ReceptorInjectionsCLINICAL-TRIALPrediabetic State03 medical and health sciencesIMPAIRED GLUCOSE-TOLERANCEDouble-Blind MethodDiabetes mellitusInternal medicineWeight LossREGRESSIONDiabetes MellitusmedicineHumansHypoglycemic AgentsObesityLiraglutidebusiness.industryBody WeightLiraglutidemedicine.diseaseClinical trialEndocrinologyDiabetes Mellitus Type 2Human medicinebusinessRisk Reduction Behavior[SDV.AEN]Life Sciences [q-bio]/Food and Nutrition[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyThe Lancet
researchProduct

Similar effectiveness of dapagliflozin and GLP-1 receptor agonists concerning combined endpoints in routine clinical practice: A multicentre retrospe…

2019

Abstract Aims According to cardiovascular outcome trials, some sodium‐glucose contransporter‐2 inhibitors (SGLT2i) and glucagon‐like peptide‐1 receptor agonists (GLP‐1RA) are recommended for secondary cardiovascular prevention in type 2 diabetes (T2D). In this real‐world study, we compared the simultaneous reductions in HbA1c, body weight and systolic blood pressure after initiation of dapagliflozin or GLP‐1RA as second or a more advanced line of therapy. Materials and methods DARWIN‐T2D was a retrospective multi‐centre study conducted at diabetes specialist clinics in Italy that compared T2D patients who initiated dapagliflozin or GLP‐1RA (exenatide once weekly or liraglutide). Data were c…

Blood GlucoseMaleGlycated Hemoglobin AEndocrinology Diabetes and MetabolismBlood PressureType 2 diabetes030204 cardiovascular system & hematologySettore MED/13 - Endocrinologiachemistry.chemical_compound0302 clinical medicineEndocrinologyGlucosidesClinical endpointMedicineDapagliflozinGLP-1 analogueMiddle AgedTreatment Outcomeglycaemic controlantidiabetic drug; dapagliflozin; GLP-1 analogue; glycaemic control; observational studyCombinationOriginal ArticleDrug Therapy CombinationFemaleType 2medicine.drugAdultmedicine.medical_specialty030209 endocrinology & metabolismGlucagon-Like Peptide-1 Receptor03 medical and health sciencesDrug TherapyGLP-1 analogue; antidiabetic drug; dapagliflozin; glycaemic control; observational studyGLP‐1 analogueInternal medicineDiabetes mellitusInternal MedicineDiabetes MellitusHumansHypoglycemic AgentsBenzhydryl CompoundsAgedRetrospective StudiesGlycated Hemoglobinantidiabetic drugantidiabetic drug; dapagliflozin; GLP-1 analogue; glycaemic control; observational study; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus Type 2; Diabetic Angiopathies; Drug Therapy Combination; Exenatide; Female; Glucagon-Like Peptide-1 Receptor; Glucosides; Glycated Hemoglobin A; Humans; Hypoglycemic Agents; Liraglutide; Male; Middle Aged; Retrospective Studies; Treatment Outcomebusiness.industryLiraglutideBody WeightRetrospective cohort studyOriginal ArticlesdapagliflozinLiraglutidemedicine.diseaseBlood pressureDiabetes Mellitus Type 2chemistryPropensity score matchingExenatideobservational studybusinessAntidiabetic drug dapagliflozin GLP-1 analogue glycaemic control observational studyDiabetic Angiopathies
researchProduct

Impact of a Mediterranean Dietary Pattern and Its Components on Cardiovascular Risk Factors, Glucose Control, and Body Weight in People with Type 2 D…

2018

This study evaluates the relation of a Mediterranean dietary pattern and its individual components with the cardiovascular risk factors profile, plasma glucose and body mass index (BMI) in people with type 2 diabetes. We studied 2568 participants at 57 diabetes clinics. Diet was assessed with the EPIC (European Prospective Investigation into Cancer and Nutrition) questionnaire, adherence to the Mediterranean diet was evaluated with the relative Mediterranean diet score (rMED). A high compared to a low score was associated with a better quality of diet and a greater adherence to the nutritional recommendations for diabetes. However, even in the group achieving a high score, only a small prop…

Blood GlucoseMaleMediterranean diet; cardiovascular risk; diabetes; glucose control; plasma lipids; relative Mediterranean diet score; Aged; Biomarkers; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Cross-Sectional Studies; Diabetes Mellitus Type 2; Female; Glycated Hemoglobin A; Humans; Lipids; Male; Middle Aged; Nutritive Value; Patient Compliance; Protective Factors; Recommended Dietary Allowances; Risk Factors; Body Mass Index; Diet Healthy; Diet Mediterranean; Feeding BehaviorGlycated Hemoglobin AMediterranean dietRecommended Dietary AllowanceCross-sectional studyHealthy DietSaturated fatBlood PressureType 2 diabetes030204 cardiovascular system & hematologyMediterraneanDiet MediterraneanDiabeteRecommended Dietary AllowancesSettore MED/13 - EndocrinologiaBody Mass Indexchemistry.chemical_compound0302 clinical medicineRisk FactorsCardiovascular Disease030212 general & internal medicineNutrition and DieteticsdiabetesLipidMiddle AgedLipidsEuropean Prospective Investigation into Cancer and NutritionCardiovascular DiseasesFemaleDiet Healthylcsh:Nutrition. Foods and food supplyNutritive ValueType 2Humancardiovascular riskCardiovascular risk; Diabetes; Glucose control; Mediterranean diet; Plasma lipids; Relative mediterranean diet score; Aged; Biomarkers; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Cross-Sectional Studies; Diabetes Mellitus Type 2; Female; Glycated Hemoglobin A; Humans; Lipids; Male; Middle Aged; Nutritive Value; Patient Compliance; Protective Factors; Recommended Dietary Allowances; Risk Factors; Body Mass Index; Diet Mediterranean; Feeding Behavior; Healthy Diet; Food Science; Nutrition and DieteticsPlasma lipidlcsh:TX341-641Article03 medical and health sciencesEnvironmental healthDiabetes mellitusMediterranean dietplasma lipidsmedicineDiabetes MellitusHumansProtective FactorAgedCross-Sectional StudieGlycated Hemoglobinglucose controlHealthybusiness.industryRisk FactorBiomarkerFeeding Behaviorrelative Mediterranean diet scoreProtective Factorsmedicine.diseaseDietCross-Sectional StudieschemistryDiabetes Mellitus Type 2Patient ComplianceGlycated hemoglobinbusinessBody mass indexBiomarkersFood Science
researchProduct